MarketBeat
05 Aug 2026, 03:04 UTC · 6h ago
Syndax Pharmaceuticals Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
05 Aug 2026, 03:04 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Syndax forecasts peak annual U.S. net revenue for Revuforj to exceed $2 billion if it secures anticipated frontline AML indications. — This sets a massive long-term valuation target and high-growth trajectory for the company's primary asset.
+0.80Total revenue for Q2 2026 grew 92% year-over-year to $72.8 million, driven by strong sales of Revuforj and Niktimvo. — Rapid top-line growth validates commercial execution and product demand for the current portfolio.
+0.60Syndax expects to report top-line results in Q4 from a Phase II trial of axatilimab (Niktimvo) in idiopathic pulmonary fibrosis and a Phase II study in frontline chronic GVHD. — These upcoming data readouts are binary catalysts that could significantly expand the addressable market for Niktimvo.
+0.50Continue reading
6 related stories
Top 1 mover · tap to explore
Revuforj is seeing expanded adoption in NPM1-mutated AML, with fewer than 15% of the 4,500 annual eligible patients having received a menin inhibitor to date. — High untapped market penetration potential suggests a sustainable runway for near-term revenue growth.
+0.40The company is developing new pipeline programs SNDX-4321 for lung cancer and SNDX-62122 for myelofibrosis, with IND submissions expected in 2026 and 2027 respectively. — While diversifying the pipeline, these are very early-stage developments with minimal short-term financial impact.
+0.20Which stocks this story touches
Reported 92% revenue growth, strong sales growth for Revuforj and Niktimvo, and positive pipeline progress.
Benefiting from the strong commercial growth and adoption of Niktimvo, which generated $60 million in net sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
